Advertisements

Affimed N.V. (AFMD) Stock Quote

Detailed Quote for Affimed N.V. (AFMD)
$ 2.075   -0.125 (-5.68%) Volume: 567.18k 4:00 PM EST 20-Feb-2018
After Hours:  $ 2.10   0.025 (+1.20%) Volume: 14.68k 7:56 PM EST 20-Feb-2018
Today 5d 1m 3m 1y more
Last Price
2.075
Change $
0.125
Change %
5.68%
Tick
  
Bid
1.20
Bid Size
100
Ask
2.30
Ask Size
1,000
Open
2.20
High
2.25
Low
2.05
Prev Close
2.20
Last Trade
02/20/18
Volume
567.18k
52 Wk Hi
2.95000004
52 Wk Low
1.14999997
Market Cap
92.69m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
44,671,364
EPS (TTM)
-0.730000019
PE Ratio
N/A
Exchange
NSD
News and Media for Affimed N.V. (AFMD)
Sector News | Topic News
News for Affimed N.V. (AFMD)
Tue, Feb 13, 2018
12:50 PM Midday Gainers / Losers (2/13/2018) - SeekingAlpha
9:17 AM Premarket Losers as of 9:05 am (2/13/2018) - SeekingAlpha
Mon, Feb 12, 2018
5:38 PM After Hours Gainers / Losers (2/12/2018) - SeekingAlpha
Sat, Feb 10, 2018
12:56 AM Finding Biotech Value In All-Time Highs - SeekingAlpha
Tue, Feb 06, 2018
9:12 AM Premarket Losers as of 9:05 am (2/6/2018) - SeekingAlpha
Mon, Feb 05, 2018
12:44 PM Midday Gainers / Losers (2/5/2018) - SeekingAlpha
Fri, Feb 02, 2018
8:00 AM Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data - SeekingAlpha
6:43 AM U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018 - SeekingAlpha
Thu, Feb 01, 2018
4:15 PM Affimed Therapeutics' Data Will Finally Trump Execution In 2018 - SeekingAlpha
12:50 PM Midday Gainers / Losers (2/1/2018) - SeekingAlpha
10:10 AM Updated data on Affimed's AFM13 shows 89% response rate in HL patients; shares up 28% - SeekingAlpha
9:18 AM Premarket Gainers as of 9:05 am (02/01/2018) - SeekingAlpha
Mon, Dec 11, 2017
1:35 PM Affimed's lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27% - SeekingAlpha
12:47 PM Midday Gainers / Losers - SeekingAlpha
Tue, Nov 28, 2017
8:00 AM Affirmed, Data Due in December, Potential Catalysts, Clinical Highlights - ACCESSWIRE IA
Tue, Nov 07, 2017
3:23 PM Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q3 2017 Results - Earnings Call Transcript - SeekingAlpha
10:05 AM Affimed Therapeutics 2017 Q3 - Results - Earnings Call Slides - SeekingAlpha
7:34 AM Affimed reports Q3 results - SeekingAlpha
Mon, Nov 06, 2017
5:30 PM Notable earnings before Tuesday's open - SeekingAlpha
Fri, Sep 29, 2017
11:55 AM Affimed (AFMD) Presents At LEERINK Partners Roundtable Series On Rare Disease And Immuno-Oncology - Slideshow - SeekingAlpha
More News for AFMD >>

Tags for Affimed N.V.

Research stocks or mutual funds related to Affimed N.V. by keywords or tags. Find companies that have a similar focus to AFMD. The keywords below have been associated to AFMD by either user submission or electronic means.